Alternative chemotherapy for acute myeloid leukemia with Down syndrome

Gregory Joey, Yuke Nelwan, Max Franz Joseph Mantik, Stefanus Gunawan, Valerie de Haas, Gertjan L. Kaspers

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review


Myeloid leukemia with Down syndrome (ML-DS) is a unique entity of acute myeloid leukemia (AML) with superior treatment response and overall survival compared with children with AML. However, despite the advances in treatment approaches, ML-DS survival rates for children in low- and middle-income countries remain poor. In this article, we describe 3 cases of ML-DS, which were treated with a novel protocol using vincristine, cytarabine, and daunorubicin plus triple intrathecal drugs. All the 3 patients successfully finished the treatment, with 2 patients in complete remission until now. One patient died because of uncontrolled bleeding for 2 days after finishing the chemotherapy regimen. Our findings indicate that using our treatment protocol, ML-DS is treatable in limited-resource settings such as that in Manado, Indonesia.

Originele taal-2Engels
TijdschriftEuropean Journal of Oncology Pharmacy
Nummer van het tijdschrift3
StatusGepubliceerd - 1 sep. 2022


Duik in de onderzoeksthema's van 'Alternative chemotherapy for acute myeloid leukemia with Down syndrome'. Samen vormen ze een unieke vingerafdruk.

Citeer dit